Trial · NCT01433263
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 | 30mg/kg BYM338 | 2.0 | Standard Deviation 8.094 | Percentage Change of TMV | |
| Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 | Placebo / Late 30mg/kg BYM338 | 0.65 | Standard Deviation 8.239 | Percentage Change of TMV | |
| Percentage Change in Body Weight From Baseline at Week 7 and Week 9 | 30mg/kg BYM338 | Week 7 (n= 15, 17) | -3.3 | Standard Deviation 5.035 | Percent Change of Weight (kg) |
| Percentage Change in Body Weight From Baseline at Week 7 and Week 9 | Placebo / Late 30mg/kg BYM338 | Week 7 (n= 15, 17) | -0.68 | Standard Deviation 4.457 | Percent Change of Weight (kg) |
| Percentage Change in Body Weight From Baseline at Week 7 and Week 9 | 30mg/kg BYM338 | Week 9 (n=14,16) | -1.8 | Standard Deviation 7.131 | Percent Change of Weight (kg) |
| Percentage Change in Body Weight From Baseline at Week 7 and Week 9 | Placebo / Late 30mg/kg BYM338 | Week 9 (n=14,16) | -0.32 | Standard Deviation 3.271 | Percent Change of Weight (kg) |
| Maximum Observed Serum Concentration (Cmax) | 30mg/kg BYM338 | 422 | Standard Deviation 142 | ng/ml | |
| Maximum Observed Serum Concentration (Cmax) | Placebo / Late 30mg/kg BYM338 | 408 | Standard Deviation 78.4 | ng/ml | |
| Time to Reach the Maximum Concentration After Drug Administration (Tmax) | 30mg/kg BYM338 | 2.05 | Inter-Quartile Range 142 | hr | |
| Time to Reach the Maximum Concentration After Drug Administration (Tmax) | Placebo / Late 30mg/kg BYM338 | 2.22 | Inter-Quartile Range 78.4 | hr | |
| Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8 | 30mg/kg BYM338 | 4.97 | Standard Deviation 7.537 | Percentage Change in LBM | |
| Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8 | Placebo / Late 30mg/kg BYM338 | 2.41 | Standard Deviation 4.625 | Percentage Change in LBM | |
| Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8 | 30mg/kg BYM338 | 0.51 | Standard Deviation 3.712 | Percentage Change in BMD | |
| Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8 | Placebo / Late 30mg/kg BYM338 | 0.14 | Standard Deviation 4.14 | Percentage Change in BMD | |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7 | 30mg/kg BYM338 | Week 4 (n=18, 23) | 917.78 | Standard Deviation 3720.491 | percentage change in number of steps |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7 | Placebo / Late 30mg/kg BYM338 | Week 4 (n=18, 23) | 63.59 | Standard Deviation 130.913 | percentage change in number of steps |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7 | 30mg/kg BYM338 | Week 7 (n=13, 22) | -17.37 | Standard Deviation 80.350 | percentage change in number of steps |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7 | Placebo / Late 30mg/kg BYM338 | Week 7 (n=13, 22) | 35.80 | Standard Deviation 119.486 | percentage change in number of steps |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7 | 30mg/kg BYM338 | Week 4 (n=18, 23) | -0.05 | Standard Deviation 10.049 | percentage change in time (minutes) |
| Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7 | Placebo / Late 30mg/kg BYM338 | Week 4 (n=18, 23) | 52.25 | Standard Deviation 207.403 | percentage change in time (minutes) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01433263/results